Results 21 to 30 of about 274,722 (228)

Epicutaneous immunotherapy with Viaskin™ Peanut in toddlers: a plain language summary.

Immunotherapy, 2023
WHAT IS THIS SUMMARY ABOUT? This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy ...
D. Stukus, Ruchi Gupta, Douglas P. Mack, Lianne Mandelbaum, D. Siri, V. Hernandez-Trujillo, Hugh A. Sampson   +6 more
semanticscholar   +3 more sources

Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature [PDF]

Journal of Translational Medicine, 2018
Background Epicutaneous immunotherapy (EPIT) is a new way of allergen administration that has a high rate of adherence and safety. The aim of this manuscript is to review clinical trials on EPIT for respiratory and food allergies published in the last 10 
Susanna Esposito, Chiara Isidori, Alessandra Pacitto, Cristina Salvatori, Laura Sensi, Franco Frati, Giuseppe Di Cara, Francesco Marcucci   +7 more
doaj   +2 more sources

Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma. [PDF]

Allergy, 2021
Background Allergen-specific immunotherapy via the skin targets a tissue rich in antigen-presenting cells, but can be associated with local and systemic side effects.
Korotchenko E, Schießl V, Scheiblhofer S, Schubert M, Dall E, Joubert IA, Strandt H, Neuper T, Sarajlic M, Bauer R, Geppert M, Joedicke D, Wildner S, Schaller S, Winkler S, Gadermaier G, Horejs-Hoeck J, Weiss R.   +17 more
europepmc   +3 more sources

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.

JAMA, 2019
Importance There are currently no approved treatments for peanut allergy. Objective To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut-allergic children.
Fleischer DM, Greenhawt M, Sussman G, Bégin P, Nowak-Wegrzyn A, Petroni D, Beyer K, Brown-Whitehorn T, Hebert J, Hourihane JO, Campbell DE, Leonard S, Chinthrajah RS, Pongracic JA, Jones SM, Lange L, Chong H, Green TD, Wood R, Cheema A, Prescott SL, Smith P, Yang W, Chan ES, Byrne A, Assa'ad A, Bird JA, Kim EH, Schneider L, Davis CM, Lanser BJ, Lambert R, Shreffler W.   +32 more
europepmc   +2 more sources

Therapeutic perspectives in food allergy [PDF]

Journal of Translational Medicine, 2020
Background In the last twenty years, several studies have been conducted in the search for new therapeutic strategies in patients with food allergy; in particular, after the failure of injection immunotherapy, three different routes of administration ...
Francesco Marcucci, Chiara Isidori, Alberto Argentiero, Cosimo Neglia, Susanna Esposito   +4 more
doaj   +3 more sources

Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons [PDF]

Frontiers in Immunology
With the recent FDA approval of the anti-IgE biologic, omalizumab, in 2024 for the treatment of food allergy, it is critical to consider the advantages and disadvantages of anti-IgE and allergen-specific immunotherapies (AITs) to help determine optimal ...
Michael D. Kulis, Jessica R. Humphrey, James W. Krempski, Edwin H. Kim, Johanna M. Smeekens, Johanna M. Smeekens   +5 more
doaj   +2 more sources

Efficacy of Epicutaneous Immunotherapy in Children with Milk-Induced Eosinophilic Esophagitis. [PDF]

Clinical Gastroenterology and Hepatology, 2020
BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is caused by an immune response to specific food allergens. There are no approved therapies beyond avoidance of the allergen(s) or treatment of inflammation.
J. Spergel, O. Elci, A. Muir, C. Liacouras, B. Wilkins, Deirdre D. Burke, Megan O. Lewis, T. Brown-Whitehorn, A. Cianferoni   +8 more
semanticscholar   +3 more sources

Epicutaneous Immunotherapy Compared with Sublingual Immunotherapy in Mice Sensitized to Pollen (Phleum pratense). [PDF]

ISRN Allergy, 2012
Background. The aim of this study was to compare the efficacy of epicutaneous immunotherapy (EPIT) to sublingual immunotherapy (SLIT) in a model of mice sensitized to Phleum pratense pollen. Methods. BALB/c mice were sensitized by sub-cutaneous route to pollen protein extract mixed treated for 8 weeks, using sham, EPIT, or SLIT.
Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Puteaux E, Dupont C, Benhamou PH.   +6 more
europepmc   +4 more sources

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.

JAMA, 2017
Importance Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials.
Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, Cheema AS, Leonard SA, Pongracic JA, Sauvage-Delebarre C, Assa'ad AH, de Blay F, Bird JA, Tilles SA, Boralevi F, Bourrier T, Hébert J, Green TD, Gerth van Wijk R, Knulst AC, Kanny G, Schneider LC, Kowalski ML, Dupont C.   +23 more
europepmc   +2 more sources

Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. [PDF]

J Allergy Clin Immunol, 2017
Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, Henning AK, Berin MC, Chiang D, Vickery BP, Pesek RD, Cho CB, Davidson WF, Plaut M, Sampson HA, Wood RA, Consortium of Food Allergy Research.   +16 more
europepmc   +2 more sources